NISCAIR Online Periodicals Repository

Research Journals >
Indian Journal of Traditional Knowledge (IJTK) >
IJTK Vol.10 [2011] >
IJTK Vol.10(4) [October 2011] >

Title: Clinical evaluation of the hepatoprotective effect of Katuki (Picrorhiza kurroa Royle ex Benth.) processed in Guduchi (Tinospora cordifolia Wild.) Miers in patients receiving lipid lowering drugs (Statins)
Authors: Singh, Harbans
Sharma, Y K
Keywords: Drug induced hepatitis
Hepatoprotective effect
Issue Date: Oct-2011
Publisher: NISCAIR-CSIR, India
IPC CodeInt. Cl.8: A01D 14/01, A01D 14/09, A01D 14/10, A01D 1/04, A01D 23/21, A01D 7/52
Abstract: The hypolipidaemic drugs have attracted considerable attention because of their potential to prevent cardiovascular disease by retarding the accelerated atherosclerosis in hyperlipidaemic individuals. Statins are the first choice drugs for primary hyperlipidaemias with raised LDL and total cholesterol levels, with or without raised triglycerides levels, as well as for secondary hypercholesterolemia. Statin therapy is commonly associated with liver damage in terms of elevated aminotransaminases. Simultaneous use of hepatotoxicity reducing formulation is desirable for successful continuation of HMG-CoA reductase inhibitor (statins) over a desired period in hyperlipidaemic patients. So, the present clinical study was planned to evaluate the hepatoprotective effect of Katuki (Picrorhiza kurroa Royle ex Benth.) processed in Guduchi [Tinospora cordifolia (Wild.) Miers], on scientific parameters. In the present clinical trial, two groups of patients receiving standardized lipid lowering drug (Atrorvastatin 20 mg, twice daily) have been studied to evaluate the hepatoprotective effect of these drugs. The first group was given 2 gm of Katuki processed in Guduchi, twice daily with statin therapy. The second group was given 500 mg of starch powder filled in capsules, twice daily with statin therapy. The trial was conducted for three months and liver functions test were periodically evaluated to assess the hepatoprotective effect of drugs under trial. At the end of the trial, trial group exhibited its hepatoprotective efficiency over the control.
Page(s): 657-660
CC License:  CC Attribution-Noncommercial-No Derivative Works 2.5 India
ISSN: 0975-1068 (Online); 0972-5938 (Print)
Source:IJTK Vol.10(4) [October 2011]

Files in This Item:

File Description SizeFormat
IJTK 10(4) 657-660.pdf70.14 kBAdobe PDFView/Open
 Current Page Visits: 504 
Recommend this item


Online Submission of Articles |  NISCAIR Website |  National Knowledge Resources Consortium |  Contact us |  Feedback

Disclaimer: NISCAIR assumes no responsibility for the statements and opinions advanced by contributors. The editorial staff in its work of examining papers received for publication is helped, in an honorary capacity, by many distinguished engineers and scientists.

CC License Except where otherwise noted, the Articles on this site are licensed under Creative Commons License: CC Attribution-Noncommercial-No Derivative Works 2.5 India

Copyright © 2015 The Council of Scientific and Industrial Research, New Delhi. All rights reserved.

Powered by DSpace Copyright © 2002-2007 MIT and Hewlett-Packard | Compliant to OAI-PMH V 2.0

Home Page Total Visits: 162359 since 01-Sep-2015  Last updated on 21-Jun-2016Webmaster: